Pieris Pharmaceuticals (Seite 6)
eröffnet am 06.01.17 13:11:27 von
neuester Beitrag 28.08.23 08:45:50 von
neuester Beitrag 28.08.23 08:45:50 von
Beiträge: 104
ID: 1.244.291
ID: 1.244.291
Aufrufe heute: 0
Gesamt: 11.896
Gesamt: 11.896
Aktive User: 0
ISIN: US7207952026 · WKN: A40A3W · Symbol: PIRS
11,720
USD
+1,03 %
+0,120 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 7,3500 | +43,84 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,110 | -13,44 | |
| 8,2200 | -13,47 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
ich auch nicht, generell ist diese Aktie extrem unberechenbar. Hab null Gefühl wie sich das weiter entwickelt...die letzten Monate war eine klare Range zwischen 3$ und 4$, mal schauen ob wir mal wieder einen Aufwärtstrend generieren...
Finde auch keine News.
Finde auch keine News.
verstanden habe ich den +1/3-Move gestern nicht:
12.11.2018
Hallbergmoos lockt internationales Unternehmen an
Pharmaunternehmen Pieris Pharmaceuticals bezieht 12.000 Quadratmeter
https://www.chemanager-online.com/themen/industriestandorte/…
--> Pieris meint es ernst. Jetzt verstehe ich auch den erhöhten Kapitalbedarf
--> dieser mMn wirklich große Gebäude-Komplex in Hallbergmoos/Nähe Flughafen München, der auch die Bestandsstandorte in der Nähe konsolidieren wird, wird für Pieris gerade umgebaut:
Rückseite; zwei Seiten sind quasi mit Baucontainer zugestellt; dort werden auch Laborräume eingerichtet nach Sichtung von entsprechenden Lieferanten-Fahrzeugen; Bilder FC, 19.11.2019
Hallbergmoos lockt internationales Unternehmen an
Pharmaunternehmen Pieris Pharmaceuticals bezieht 12.000 Quadratmeter
https://www.chemanager-online.com/themen/industriestandorte/…
--> Pieris meint es ernst. Jetzt verstehe ich auch den erhöhten Kapitalbedarf
--> dieser mMn wirklich große Gebäude-Komplex in Hallbergmoos/Nähe Flughafen München, der auch die Bestandsstandorte in der Nähe konsolidieren wird, wird für Pieris gerade umgebaut:
Rückseite; zwei Seiten sind quasi mit Baucontainer zugestellt; dort werden auch Laborräume eingerichtet nach Sichtung von entsprechenden Lieferanten-Fahrzeugen; Bilder FC, 19.11.2019
Trading Spotlight
Antwort auf Beitrag Nr.: 61.627.545 von faultcode am 04.10.19 19:04:10mal wieder den Kapitalbedarf decken:
4.11.
Pieris Pharmaceuticals Announces $32 Million Private Placement and Potential Funding Mechanism for PRS-060 Co-development Opt-in
https://www.accesswire.com/565143/Pieris-Pharmaceuticals-Ann…
...Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it has entered into a securities purchase agreement with existing and new institutional investors to raise $32 million.
The private placement was led by BVF Partners L.P., with significant additional participation from EcoR1 Capital, Aquilo Capital Management, Surveyor Capital (a Citadel company), and Samsara BioCapital.
The private placement will consist of 9,014,960 units, at a price of $3.55 per unit. Each unit will consist of (i) one share of Pieris' common stock or 0.001 non-voting Series C convertible preferred stock, and (ii) one immediately-exercisable warrant to purchase one share of common stock at an exercise price of $7.10 per share. Each share of non-voting Series C convertible preferred stock is convertible into 1,000 shares of Pieris common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would own more than 9.99% of the total number of shares of Pieris common stock then outstanding.
The warrants are intended to facilitate Pieris' exercise of its co-development option for PRS-060/AZ1402 following the conclusion of a positive phase 2a study. If top-line results of that study disclose achievement of the primary efficacy endpoint and the stock reaches a pre-specified price, then the warrants will expire sixty days following such disclosure and may only be exercised for cash. Otherwise, the warrants will be exercisable for a period of five years from the date of issuance.
The closing of the financing is expected to take place on or about November 6, 2019 and is subject to standard closing conditions. Pieris expects to use the proceeds from the financing for continued development of its immuno-oncology franchise, including PRS-343, its 4-1BB/HER2 bispecific, and PRS-344, its 4-1BB/PD-L1 bispecific in co-development with Servier. The Company also expects to use these proceeds for advancement of its proprietary pipeline of inhalable respiratory drug candidates following proof-of-mechanism with respect to PRS-060/AZ1402, validating the inhaled Anticalin platform as a potential drug class, as well as for working capital and general corporate purposes.
...
4.11.
Pieris Pharmaceuticals Announces $32 Million Private Placement and Potential Funding Mechanism for PRS-060 Co-development Opt-in
https://www.accesswire.com/565143/Pieris-Pharmaceuticals-Ann…
...Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it has entered into a securities purchase agreement with existing and new institutional investors to raise $32 million.
The private placement was led by BVF Partners L.P., with significant additional participation from EcoR1 Capital, Aquilo Capital Management, Surveyor Capital (a Citadel company), and Samsara BioCapital.
The private placement will consist of 9,014,960 units, at a price of $3.55 per unit. Each unit will consist of (i) one share of Pieris' common stock or 0.001 non-voting Series C convertible preferred stock, and (ii) one immediately-exercisable warrant to purchase one share of common stock at an exercise price of $7.10 per share. Each share of non-voting Series C convertible preferred stock is convertible into 1,000 shares of Pieris common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would own more than 9.99% of the total number of shares of Pieris common stock then outstanding.
The warrants are intended to facilitate Pieris' exercise of its co-development option for PRS-060/AZ1402 following the conclusion of a positive phase 2a study. If top-line results of that study disclose achievement of the primary efficacy endpoint and the stock reaches a pre-specified price, then the warrants will expire sixty days following such disclosure and may only be exercised for cash. Otherwise, the warrants will be exercisable for a period of five years from the date of issuance.
The closing of the financing is expected to take place on or about November 6, 2019 and is subject to standard closing conditions. Pieris expects to use the proceeds from the financing for continued development of its immuno-oncology franchise, including PRS-343, its 4-1BB/HER2 bispecific, and PRS-344, its 4-1BB/PD-L1 bispecific in co-development with Servier. The Company also expects to use these proceeds for advancement of its proprietary pipeline of inhalable respiratory drug candidates following proof-of-mechanism with respect to PRS-060/AZ1402, validating the inhaled Anticalin platform as a potential drug class, as well as for working capital and general corporate purposes.
...
Antwort auf Beitrag Nr.: 57.879.453 von faultcode am 31.05.18 17:41:57die PRS-060-Meldung vom 26.9. (https://www.pieris.com/news-and-events/press-releases/detail…) kam nicht gut an:
Antwort auf Beitrag Nr.: 61.127.090 von Schnurzelpurzel99 am 29.07.19 16:17:33Pieris präsentiert demnächst daten zum Asthma Projekt und gestern wurde bekannt, dass sie dies als Latebreaker tun dürfen. Zudem ist der Titel vielversprechend. Deshalb der Anstieg!
Starker Anstieg heute, so ohne Nachrichten.
Antwort auf Beitrag Nr.: 60.269.295 von schnappi am 03.04.19 18:45:24Raus aus dem Bollinger wollen wir ja nicht. Schön langsam steigen, innerhalb des Bandes.
Heute Konferenzmeldung für 08.04.2019;
https://www.pieris.com/news-and-events/press-releases/detail…
Heute Konferenzmeldung für 08.04.2019;
https://www.pieris.com/news-and-events/press-releases/detail…
Durchsuchen
Pieris Pharmaceuticals
